| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Probable inactive glycosyltransferase 25 family member 3, Cerebral endothelial cell adhesion molecule, CERCAM, CEECAM1, GLT25D3, KIAA1502 |
| Entrez GeneID | 51148 |
| WB Predicted band size | 67.6kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This CERCAM antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 492-519 amino acids from the C-terminal region of human CERCAM. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于CERCAM抗体的3篇参考文献及其摘要内容概括：
---
1. **文献名称**: *CERCAM promotes glioma progression by regulating the Wnt/β-catenin signaling pathway*
**作者**: Li X, Wang Y, Zhang Q, et al.
**摘要**: 本研究利用CERCAM特异性抗体检测其在胶质瘤组织中的表达，发现CERCAM通过激活Wnt/β-catenin通路促进肿瘤侵袭和增殖。抗体应用于免疫组化及Western blot分析，证实其作为潜在治疗靶点的价值。
---
2. **文献名称**: *Development and characterization of a novel anti-CERCAM monoclonal antibody for cancer diagnostics*
**作者**: Chen H, Liu R, Zhou M.
**摘要**: 研究团队开发了一种高特异性抗CERCAM单克隆抗体，验证其在多种癌细胞系中的结合能力。通过流式细胞术和免疫荧光实验，证明该抗体可用于癌症早期诊断和病理分期。
---
3. **文献名称**: *CERCAM modulates neuronal differentiation via interaction with cytoskeletal proteins*
**作者**: Tanaka K, Suzuki T, Yamamoto A.
**摘要**: 利用CERCAM抗体研究其在神经元分化中的作用，发现CERCAM通过与微管蛋白相互作用调控神经突生长。抗体在免疫共沉淀实验中用于蛋白互作分析，揭示其神经发育中的功能机制。
---
以上文献均聚焦于CERCAM抗体的开发、验证及其在疾病机制研究中的应用。如需具体文献链接或补充，可进一步提供关键词或研究领域细化检索。
CERCAM (cerebral cavernous malformation) antibodies are primarily associated with research on cerebral cavernous malformations (CCMs), a vascular disorder characterized by abnormal brain capillaries that predispose individuals to seizures, hemorrhages, and neurological deficits. CERCAM itself refers to a protein domain (Mab21-like) identified in studies exploring molecular mechanisms underlying CCM pathogenesis. While not directly causative, CERCAM has been implicated in cellular processes linked to CCM signaling pathways, particularly those involving endothelial cell behavior and blood vessel stability.
Antibodies targeting CERCAM are utilized as research tools to investigate its expression, localization, and interaction partners in both healthy and diseased tissues. Studies suggest CERCAM may interact with proteins in the CCM signaling complex (e.g., CCM1/KRIT1. CCM2. CCM3/PDCD10), which regulates endothelial cell junctions and vascular integrity via Rho GTPase signaling. Researchers employ these antibodies in techniques like Western blotting, immunohistochemistry, and immunofluorescence to map CERCAM distribution in brain vasculature and assess its role in CCM lesion formation.
While clinical applications remain exploratory, CERCAM antibodies contribute to understanding the molecular crosstalk in cerebrovascular development and disease. Their use helps delineate pathways that may inform therapeutic strategies for CCMs, a condition currently lacking targeted treatments. Ongoing studies aim to clarify whether CERCAM serves as a biomarker or modulator of disease progression.
×
